News, insights and milestones

A rare disease is a condition that affects a small percentage of the population, yet collectively impacts hundreds of millions of people worldwide. Often genetic in origin, rare diseases can be difficult to diagnose and treat, creating significant challenges for patients and healthcare systems. Read more about their global impact, diagnostic challenges and treatment development.

During the COVID-19 pandemic, Masters Speciality Pharma adapted its logistics, packaging, and supply chain to ensure life-saving medicines reached patients in developing countries. Read more about how innovation, teamwork, and resilience turned challenges into opportunities to improve global access to critical treatments.

Although individually uncommon, rare diseases collectively affect millions worldwide. Many are genetic, while others are triggered by environmental or unknown factors — yet only a small percentage have approved treatments. Discover the causes of rare diseases, the challenges in developing therapies, and how improving access to medication is transforming lives.

Rare genetic and congenital diseases affect millions worldwide, yet most have no approved treatments. Advances in gene therapy, research, and regulatory support are helping change this landscape. Read more about the challenges, emerging therapies, and how Masters Speciality Pharma is improving access to life-saving medications for patients in emerging markets.

Hydroxyurea is a proven disease-modifying therapy for Sickle Cell Anaemia, yet patient responses vary significantly. Emerging research suggests genetic factors may influence treatment effectiveness and HbF levels. Read more about the latest findings on genetic determinants, treatment variability and the future of personalised care in Sickle Cell Disease.

Sickle Cell Disease (SCD) is a serious inherited blood disorder that causes red blood cells to become misshapen, blocking blood flow and reducing oxygen delivery throughout the body. This can lead to severe pain, anaemia and life-threatening complications.Learn more about its causes, global impact and treatment options.

With decades of experience in temperature-controlled logistics and GxP-compliant distribution, Masters Speciality Pharma ensures safe, reliable delivery of life-saving medicines to emerging markets. Read more about our expertise, innovative supply chain solutions, and commitment to maintaining product integrity from sourcing to patient.

For over 38 years, Masters Speciality Pharma has worked to provide essential medicines to emerging markets, navigating complex regulations, drug shortages, and diverse patient needs. Read more about how the company transforms global supply chains, develops specialised products, and ensures patients have access to life-saving therapies worldwide.

Founded in 1984 by Dr Zulf Masters OBE, Masters Speciality Pharma provides life-saving medicines to hospitals and patients in over 75 countries, focusing on emerging markets and rare disease treatments. Read more about our global reach, trusted partnerships, and mission to improve patient access to essential medicines worldwide.

Elstree, 18 June 2019 – Masters Speciality Pharma (“Masters”), a UK-headquartered global pharmaceutical company specialising in the global distribution of high-quality, life-changing medicines, today announces it has been appointed to be the exclusive UK distributor of Siklos®, for the treatment of Sickle Cell Disease (SCD). Siklos® (hydroxycarbamide) 100mg and 1000mg will be distributed by Masters to hospitals around the UK.